Europe Point Of Care Poc Tb Drug Resistant Tb Testing Market Report: Market Size & Forecast 2026

POC TB and drug-resistant TB testing refers to diagnostic platforms capable of identifying active TB infection and key resistance mutations within hours, rather than the days or weeks required by conventional culture-based methods. The European market is part of a wider diagnostics landscape valued at approximately $57.3 billion in 2025, with the POC TB segment expanding at a compound annual growth rate of around 8.0%. Growth is concentrated in molecular diagnostics, particularly cartridge-based PCR and ultra-sensitive NAAT systems, while immunoassays and lateral-flow tests serve as lower-cost complements in primary-care settings.

• •Molecular diagnostics (PCR, NAAT, isothermal amplification) account for the largest share of test revenues in Europe.
• •End users are dominated by clinics and hospitals, with growing uptake in mobile units, refugee health programs, and community screening.
• •Public procurement by national TB programs and the WHO European Region shapes a significant share of demand.

The resurgence of TB in Eastern European countries, including high-burden settings in Eastern Europe and Central Asia, is the single most important demand driver, with MDR-TB and extensively drug-resistant TB (XDR-TB) cases continuing to be reported across the region. Technological progress in cartridge-based molecular platforms has cut time-to-result from days to under two hours, making decentralized testing clinically and economically viable. Policy alignment between the EU, the European Centre for Disease Prevention and Control (ECDC), and the WHO End TB Strategy is also accelerating adoption through funded screening programs and updated testing guidelines.

• •High MDR-TB prevalence in Eastern Europe, including the Baltic states, is driving rapid test uptake.
• •WHO and ECDC endorsements of molecular POC tests are supporting reimbursement and guideline inclusion.
• •Innovation in low-complexity, battery-powered NAAT platforms is enabling use in remote and resource-limited European settings.

By test type, the market is split between molecular diagnostics, which leads on accuracy and speed, and immunoassays, which remain relevant for triage and cost-sensitive applications. By end use, clinics and hospitals dominate, but reference laboratories and outreach programs represent growing segments. Geographically, Western Europe (Germany, France, the UK, Italy, Spain) leads in revenue due to advanced healthcare infrastructure and higher per-test reimbursement, while Eastern Europe (Romania, Poland, the Baltic states, Bulgaria, Ukraine) is the fastest-growing region because of higher TB and MDR-TB incidence.

• •Molecular diagnostics hold the majority revenue share, with immunoassays serving as lower-cost adjuncts.
• •Clinics and hospitals are the primary end-use segment, followed by reference labs and outreach programs.
• •Eastern European countries with high MDR-TB burdens are the fastest-growing markets within Europe.

What are the recent trends and outlook?

The strongest near-term trend is the rollout of ultra-sensitive NAAT platforms capable of detecting TB and resistance mutations in under two hours from raw sputum, replacing smear microscopy as the frontline test in many European networks. Companion diagnostics for new and repurposed TB drugs, including bedaquiline, delamanid, pretomanid, and linezolid, are also shaping test design, as clinicians increasingly need rapid genotypic data to guide regimen selection. Looking ahead, the market is expected to continue growing at roughly 8.0% annually through the end of the decade, supported by digital health integration, expanded MDR-TB screening among migrants and high-risk groups, and ongoing EU funding for cross-border TB control.

• •Ultra-sensitive, sample-to-answer NAAT platforms are displacing smear microscopy as the European frontline test.
• •Resistance detection is broadening from rifampicin to fluoroquinolones, isoniazid, and second-line injectables to support newer drug regimens.
• •Digital connectivity and cloud-based reporting are becoming standard features in modern POC TB systems.